Committed to addressing patients with unmet needs.

Medicines

We are committed to expanding our portfolio and our pipeline in therapeutic areas that can leverage our unique expertise and growing our global footprint.

We believe all people, including those who live with complex conditions, deserve new and better therapeutic options.

As part of our commitment to patients with unmet needs, we continually work to expand the science behind our therapies, acquire rights to develop new medicines, and partner with researchers, academia and other industry leaders to advance molecules with great potential to create new or better standards of care.

Neuroscience

As a long-time leader in sleep medicine, Jazz has been at the forefront of providing therapies and support for our patients living with serious, debilitating neurologic disorders. More recently we have expanded into additional disease areas with high unmet needs, including rare, severe childhood-onset epilepsy, through our acquisition of GW Pharmaceuticals. We provide novel, life-changing medicines for people living with serious conditions, and we continue to expand our reach and capabilities to discover and develop new therapies that help people redefine what is possible in their lives.

We prioritize developing new medicines where others have not, to benefit people with limited options. For most of the disease areas within Jazz’s focus, there were either no suitable treatment options or limited effective treatment options until we developed or made one available. Learn more about our R&D.

Hematology and Oncology

As we advance our work in oncology, we continue to focus on people for whom we can have the greatest impact, developing therapies that have the potential to save lives or enable people to live longer, healthier lives. Our focus is in the areas of relapsed small cell lung cancer, acute leukemias, both lymphocytic and myeloid (ALL and AML) and for patients who develop an ultra-rare complication of hematopoietic stem cell transplantation (HSCT), known as veno-occlusive disease (VOD).

While the oncology community is large, as part of our commitment to patient populations with high unmet needs, we have honed in on smaller groups of people and pediatric patients facing unique challenges. These patients face difficult odds, with limited treatment options and limited survival from complex conditions including acute leukemias, complications of bone marrow transplant and solid tumors. Learn more about our R&D.

Our Medicines

Learn more about Our Medicines.